Botanix Pharmaceuticals

BOT.AXPhase 3

Perth, AustraliaFounded 2007botanixpharma.com

Botanix Pharmaceuticals is a global healthcare innovator focused on transforming the treatment landscape for common yet underserved dermatological conditions and infections. The company's key achievement is the FDA approval and US commercial launch of Sofdra™, its first-in-class topical anticholinergic for hyperhidrosis, which is also approved and launched in Japan and South Korea through partners. With a mature pipeline targeting acne, rosacea, atopic dermatitis, and antimicrobial resistance (MRSA), and led by a world-class team with extensive dermatology drug development and commercialization expertise, Botanix is strategically positioned to capture significant market opportunities.

Market Cap

$66.7M

Founded

2007

Focus

Drug DeliverySmall Molecules

BOT.AX · Stock Price

USD 0.04663.09 (-99.99%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Permetrex™ transdermal delivery technology for enhanced topical drug delivery, coupled with deep expertise in the pharmaceutical application of synthetic cannabidiol (CBD) for its anti-inflammatory and antimicrobial properties.

Pipeline Snapshot

10 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
Sofpironium Bromide, 15% + Vehicle	Axillary Hyperhidrosis	Phase 3
Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15%	Primary Axillary Hyperhidrosis	Phase 3
Sofpironium Bromide Gel, 15% + Vehicle	Axillary Hyperhidrosis	Phase 3
BTX 1503 + Vehicle	Acne Vulgaris	Phase 2
BTX 1204 + Vehicle	Atopic Dermatitis	Phase 2

Funding History

Total raised: $30.5M

Placement$15MUndisclosedJun 15, 2022

Placement$10.3MUndisclosedDec 15, 2020

IPO$5.2MUndisclosedJul 1, 2015

Opportunities

Significant growth opportunities exist from the successful US commercialization of Sofdra™ in the large hyperhidrosis market.

Further upside lies in advancing the synthetic CBD pipeline into major dermatology indications like acne and rosacea, and in addressing the global antimicrobial resistance crisis with BTX 1801.

Ex-US partnership deals for pipeline assets could provide additional non-dilutive funding.

Risk Factors

Key risks include commercial execution challenges for Sofdra's launch, clinical trial failures for earlier-stage pipeline assets, ongoing reliance on external financing, and intense competition in all target therapeutic areas.

Regulatory hurdles in new markets also pose a risk.

Competitive Landscape

Sofdra™ competes in hyperhidrosis with topical antiperspirants, oral anticholinergics, and procedures like Botox, differentiating via its FDA-approved topical gel formulation. Its dermatology pipeline will enter crowded markets (acne, rosacea) and must differentiate based on synthetic CBD's novel mechanism. BTX 1801's potential advantage in MRSA is a novel, resistance-avoiding mechanism of action.